The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column examines issues related to the preparation, dispensing, and administration of cancer chemotherapy and reviews agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
HealdP.W., DuvicM.Palliation and remission of erythrodermic cutaneous T-cell lymphoma with a novel oral RXR-selective retinoid [Abstract 428]. Annual Meeting, American Society of Hematology. New Orleans, LA; December 3–7, 1999.
2.
MillerV.A., BenedettiF.M., RigasJrInitial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol.1997; 15(2): 790–5.
3.
Anonymous.Phase II/III data are favorable for Ligand's Targretin™ capsules [press release]. Today's News, PR Newswire; September 29, 1997. www.prnewswire.com.
4.
RizviN.A., MarshallJ.L., DahutW.A Phase I study of LGD1069 in adults with advanced cancer. Clin Cancer Res.1999; 5(7): 1658–64.
5.
Anonymous.Improvement seen in 43 percent of cancer patients treated with Ligand's Targretin™ [press release]. Today's News, PRNewswire; March 24, 1997. www.prnewswire.com.
6.
GlantzM.J., JaeckleK.A., ChamberlainM.C.A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res.1999; 5(11): 3394–402.
7.
GlantzM.J., LaFolletteS., JaeckleK.A.Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol.1999; 17(10): 3110–6.
